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I. Introduction 
 
 Racial and ethnic minorities persistently classify as low performance with respect to 
health indicators.
1
   Specifically, infants born to black women are 1.5 to 3 times more likely to 
die before their first birthday than those born to women of other races/ethnicities and cancer is 
the second leading cause of death for most racial and ethnic minorities.
2
  Even more, African 
Americans, American Indians, and Alaska Natives are twice as likely to have diabetes as white 
individuals.”3  Health disparities, as defined by the National Conference of State Legislatures 
[hereinafter the NCSL], “refers to population specific differences in the presence of disease, 
health outcomes, quality of health care and access to health care services that exist across racial 
and ethnic groups.”4  Because of these low health indicators it would seem that minorities, 
particularly African Americans, would take measures to improve their health.  However, the 
opposite holds true.   African Americans are regarded as distrustful of clinical research which in 
turn impacts health outcomes and quality of life.  This paper will address African American 
perceptions of clinical research and how those perceptions in turn negatively impact the health 
decisions of this minority group.  A public health and community based health approach that 
educates minorities on the legal and ethical protections available should be explored to alter 
minority perceptions. 
 Supporters of efforts to improve African American health defend the notion that the 
pharmaceutical industry can assist in debunking African American perceptions of clinical 
                                                            
1. National Conference of State Legislature [hereinafter NCSL], Disparities in Health, available at 
http://www.ncsl.org/issues-research/health/health-disparities-overview.aspx, (Jan. 2012).  
2. Id.  See also Joon-Ho Yu, Sara Goering, Stephanie M. Fullerton, Race-Based Medicine and Justice as 
Recognition:  Exploring the Phenomenon of BiDil, 18 Cambridge Quarterly of Healthcare Ethics (UK), 57, (2009) 
also stating that racial health disparities have been documented for cardiovascular disease, cancer, diabetes, 
HIV/AIDS, and numerous other diseases; Department of Health & Human Services, Fact Sheet:  Preventing Infant 
Mortality, press release at http://www.hhs.gov/news/factsheet/infant.html (2006) last accessed Apr. 20, 2013 
defining infant mortality as an infant dying before his/her first birthday.    
3. Id.  
4. Id.  
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research.
5
  Yu and his co-authors “believe that African American community leaders capitalized 
on an opportunity to bring attention to African American health issues” with respect to the drug 
BiDil a heart failure drug.
6
  BiDil is linked to remedying health care disparities because it 
specifically targets the African American population who disproportionately suffer from heart 
disease.
7
  The link between improving health care disparities and pharmaceutical drug marketing 
research is one mechanism to further decrease the disparities between minorities and other racial 
populations.  Marketing is a powerful tool to not only advance the pharmaceutical drug’s profit 
margin but to also educate the minority population on the advantages of seeking treatment. 
   Part I of this paper will introduce the issues surrounding public perceptions of clinical 
research and the access issues in the African American community.  Part II will explore 
historical clinical practices and outline early historical events, the current paradigm implemented 
in current drug development and clinical trials, and minority perspectives on recent 
developments. Part III will explore health indicators specifically access to pharmaceutical drugs 
as a health indicator.  Part IV will then discuss the drug BiDil and how it has improved minority 
perceptions in clinical research; it will also set forth several of the criticisms of the development 
and approval history of the drug.  Part V will address methods of improving addressing minority 
perceptions of clinical research through public health and community based education programs 
that specifically target African American populations.  Part VI will conclude with 
recommendations. 
 
 
 
                                                            
5. Yu et. al, supra note 2.  
6. Id.  
7. Id.  
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II. Historical “Clinical” Practices  
 
 Historically, African Americans were discriminated against not only in social and cultural 
contexts, but were also discriminated against in health care clinical research practices.
8
  
Unfortunately, “the deeply ingrained habits, customs, and practices of racism are not easily 
uprooted.”9  Before civil rights legislation was passed, hospitals prevented African American 
patients and physicians from using their facilities.
10
  Despite legislative efforts to equalize 
treatment between whites and minorities, separate but equal legislation only perpetuated 
discrimination and inferior treatment of minorities by providing federal funds to health care 
entities who maintained racially segregated facilities.
11
 “Until 1964, the nation infused either 
slavery, legal subordination, or overt cultural subordination into its health care system.”12  Title 
VI of the Civil Rights Act of 1964 made it illegal for health care entities receiving federal 
funding to discriminate on the basis of race.
13
 
 African American attitudes of health care research are linked to racism towards 
minorities by the medical community.
14
  Looming doubts about “the true intentions” of health 
care providers furthers the divide in the provision and advancement of health care between 
                                                            
8. Patricia A. King, The Law-Medicine Center 50th Anniversary Symposium:  The Field of Health Law:  Its 
Past and Future:  Reflections on Race and Bioethics in the United States, 14 HEALTH MATRIX 149 (2004).  Stating 
that differential and negative treatment of African Americans was pervasive in the health care system in the early 
20th century with studies such as Tuskegee. 
9. Id. at 151.  
10. Brian D. Smedley, et. al., Unequal Treatment:  Confronting Racial and Ethnic Disparities in Health Care, 
Institute of Medicine.  Washington D.C.:  National Academic Press (2002).  
11.  See Simkins v. Moses Cone Memorial Hosp., 323 F.2d 959 (5th Cir. 1963), cert. denied, 376 U.S. 938 
(1964). 
12. King supra note 1 at 151.  
13. Civil Rights Act of 1964, Pub. L. No. 88-352, 78 Stat. 240 (codified as amended at 42 U.S.C. §§ 2000d-
2000d-1 (2000)).  
14. Harriet A. Washington, MEDICAL APARTHEID: THE DARK HISTORY OF MEDICAL 
EXPERIMENTATION ON BLACK AMERICANS FROM COLONIAL TIMES TO THE PRESENT (Doubleday) 
(2007).  
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African Americans and Caucasians.
15
  The Tuskegee Syphilis Study is the most notorious 
historical event that is often attributed to minority distrust of clinical research;
16
 however, 
distrust of clinical research among blacks began prior to public awareness of what actually 
occurred.
17
  In the antebellum south, African Americans were often used on “dissecting tables, 
operating amphitheaters, classroom or bedside demonstrations, and experimental facilities.”18  
Blacks were a particularly vulnerable population as they were easily identified because of their 
skin color and lack of protection in the eyes of the law.
19
       
 During this time antebellum period many medical institutions requested black patients for 
their facilities.
20
  This was particularly attractive for slave owners who could send their slaves for 
low-cost treatments and beneficial for these medical institutions that needed test subjects.
21
  Even 
though whites were also used as subjects during this time, blacks were used in far greater 
proportion.
22
   
 Two notable events occurred prior to the turn of the 20th century.  The first involved 
John “Fed” Brown, a slave who was subjected to experiments at the hands of a Georgia 
physician, Dr. Hamilton.
23
  Dr. Hamilton was performing experiments to determine how to 
                                                            
15. Isabel Wilkerson, Medical Experiments Still Haunt Blacks, N.Y. TIMES, June 3, 1991, available at 
query.nytimes.com/gst/fullpage.html?res=9D0CEEDD1E38F930A35755C0A967958260 [hereinafter Wilkerson]; 
Vanessa Northington Gamble, Under the Shadow of Tuskegee: African-Americans and Health Care, 87 AM. J. 
PUB. HEALTH 1773, 1776 (1997) [hereinafter Under the Shadow].  See also Ronald Roach, History's Burden: 
After Decades of Neglect, an Academic Research Agenda is Being Built Around Health Disparities, 20 BLACK 
ISSUES HIGHER EDUC. 1, 18 (May 8, 2003), available at findarticles. 
com/p/articles/mi_m0DXK/is_6_20/ai_101939864 [hereinafter History's Burden].  
16. Discussed in II.A, infra page 6.  
17. Under the Shadow at 1773. 
18. Todd L. Savitt, “The Use of Blacks for Medical Experimentation and Demonstration in the Old 
South,”JOURNAL OF SOUTHERN HISTORY 331 (1982). 
19. Id. at 332.  
20. Id. at 333.  
21. Id.  
22. Under the Shadow at 1774.  
23. Louis Alexis Chamerovzow, Slave Life in Georgia:  A Narrative of the Life, Sufferings, and Escape of John 
Brown, A Fugitive Slave Now in England, electronic edition, 45 available at 
http://docsouth.unc.edu/neh/jbrown/jbrown.html.  
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remedy sun-stroke.
24
  In Brown’s recount of the events he described how Dr. Hamilton asked 
permission of his owner, Stevens, who “never inquired what was going to be done” and even if 
Brown had known what was going to be done he could not himself refuse participation.
25
  Dr. 
Hamilton had a hole dug into the ground filled with wood and set a fire.
26
  Dr. Hamilton then 
forced Brown into the pit naked to sit with various mechanisms maintaining the heat inside.
27
  
Brown was provided with various medications; however, the experiments did not conclude until 
after Brown passed out.
28
  Between the series of experiments Brown was placed on a diet and 
bled every other day; after he became weak from this experiment Dr. Hamilton began an 
experiment to ascertain how deep Brown’s skin went.29  In an effort to ascertain how deep 
Brown’s skin went Dr. Hamilton he applied blisters to Brown’s hands, legs, and feet and 
continued to create blisters until a layer of dark skin formed.
30
  
 In a second event, a study conducted in Alabama slaves were used for gynecological 
experiments.  Dr. J Marion Sims, now known as the founder of modern surgical gynaecology, 
developed an operation for the cure of vesicovaginal fistula.
31
  Dr. Sims was able to develop this 
cure by using slave subjects that he housed in hospital behind his home in Montgomery, 
Alabama.
32
  One slave in particular underwent thirty operations by Dr. Sims, who was able to 
repair holes in her bladder and rectum.
33
  In total, Dr. Sims had seven subjects who involuntarily 
                                                            
24. Id.   
25. Id.  
26. Id.  at 46. 
27. Id.  
28. Id.  
29. Chamerovzow, supra note 23 at 47-48.  
30.  Id. at 48; see also Alondra Nelson, Unequal Treatment, Washington Post, Jan. 7, 2007 at 
http://www.washingtonpost.com/wp-dyn/content/article/2007/01/05/AR2007010500180.html last accessed Apr. 20, 
2013 stating that the study to determine how deep Brown’s skin went was without therapeutic value. 
31. LL Wall, The Medical Ethics of Dr. J Marion Sims:  A Fresh Look at the Historical Record, 32 (6) J. MED. 
ETHICS 346 (2006). 
32. Id.  
33. Id.  
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underwent experimentation.
34
  Procedures were performed without anesthetics, and one subject 
almost died.
35
  Experiments such as this and the one involving John Brown were only the 
beginning of unethical experiments that finally culminated with the Tuskegee experiment.   
A. The Tuskegee Syphilis Study  
 
 A seminole event in the realm of race, genetics, and research is the Tuskegee Syphilis 
Study.  The Tuskegee study began in 1932 at the behest of the United States Public Health 
Services [hereinafter USPHS] in collaboration with the Tuskegee Institute.
36
  The study was 
entitled “Tuskegee Study of Untreated Syphilis in the Negro Male,” which aimed to study the 
effects of syphilis on black males.
37
  These results would then be used to validate certain drug 
treatments targeted for minorities.
38
   
 There were 600 subjects involved in the study; of that number 399 had syphilis while 201 
were disease free.
39
  Black men, most of which were sharecroppers, between 25 and 60 years old 
were targeted for the study, especially those who tested positive for the disease.
40
 The black men 
were told they were being treated for “bad blood” and subjected to research without their 
                                                            
34. Durrenda Ojanuga, The Medical Ethics of the Father of Gynaecology, Dr J Marion Sims, 19 J. MED. 
ETHICS 28, 29 (1993). 
35. Id.  
36.  American Health Lawyers Association, Patient-Tailored Medicine, Part One:  The Impact of Race and 
Genetics on Medicine, Vol. 2 No. 1 J. HEALTH & LIFE SCI. L. 1, 11 (2008); see also CDC, U.S. Public Health 
Services Syphilis Study at Tuskegee:  The Tuskegee Timeline, available at 
http://www.cdc.gov/tuskegee/timeline.htm (2011) [hereinafter The Impact of Race & Genetics]. 
37 . Tuskegee Timeline. 
38. Id.  
39. Id. see also Tuskegee Syphillis Study Ad Hoc Advisory Panel, Final Report: Report on Charge 1-A (Apr. 
28, 1973), biotech. law.lsu.edu/cphl/history/reports/tuskegee/report1.pdf [hereinafter Report on Charge I-A] stating 
that the researchers never actually documented the reason for the study and that the subjects to the study were not 
given information about possible effects of the study. 
40. Allan M. Brandt, Racism and Research: The Case of the Tuskegee Syphilis Experiments, in TUSKEGEE'S 
TRUTHS: RETHINKING THE TUSKEGEE SYPHILIS STUDY 1, 15, 18 (Susan M. Reverby ed., University of 
North Carolina Press) (2000), available at http://www.sociology101.net/readings/Racism-And-Research.pdf 
[hereinafter Racism and Research].  
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informed consent.
41
  Unfortunately, the treatments involved did not cure the disease and the 
treatments that were supposed to only last six months went on for forty years.
42
  The men 
received medical exams, free food, and burial insurance as compensation for their participation 
in the study.
43
 
 The study was conducted in Macon County, Alabama.
44
  Macon County was particularly 
interesting for the researchers because evidence obtained during demonstration studies during 
1930-1932 showed a high rate of syphilis among the black population in Macon.
45
  These initial 
demonstration studies were funded by the Julius Rosenwald Fund.
46
  Culturally, this population 
was poorly viewed and vulnerable because the illiteracy rate was pervasive.
47
  Later research was 
financially supported by the USPHS and a grant from the Milbank Memorial Fund which gave 
$50 to each of the subjects for their participation in the study.
48
   
 The fact still remains, “treatment [that] could have cured them was deliberately withheld, 
and many of the men were prevented from seeing physicians who could have cured them.”49  
Penicillin became available in the early 1950s which could effectively treat the disease.
50
  In 
1969, the Tuskegee study was reaffirmed by the Center for Disease Control and even gained 
                                                            
41. Tuskegee Timeline.  
42. Id.  
43. Id.  
44. Tuskegee University, About the USPHS Syphilis Study, available at 
http://www.tuskegee.edu/about_us/centers_of_excellence/bioethics_center/about_the_usphs_syphilis_study.aspx 
(2013).  
45. Report on Charge I-A at 2.  
46. Racism and Research at 2-3.  
47. Id.  
48. Id.  
49. Racism and Research at 1.  
50. Id. See also Tuskegee Timeline which states that in 1945 Penicillin was accepted as the preferred treatment 
for syphilis, 1947 USPHS established “Rapid Treatment Centers” to treat syphilis, but the men involved in the study 
were prohibited from obtaining treatment. 
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support of medical associations such as the American Medical Association and National Medical 
Association.
51
   
 The study did not end until 1972 when the Department of Health, Education, and Welfare 
[hereinafter HEW] insisted that the study cease after news media reported on the existence of the 
study.
52
  Only seventy-four of the subjects were alive when the study was brought to public 
attention.
53
 HEW appointed an investigatory committee which found, among other things, that 
the study was unethical and the benefits of the study were not justified in comparison to the 
enormous risk undertaken by the subjects.
54
  The study “has come to symbolize racism in 
medicine, misconduct in human research, the arrogance of physicians, and government abuse of 
black people.”55   
 In 1997, President Clinton apologized on behalf of the nation and recognized that this 
atrocity had far reaching effects that extended beyond the participants in the study.
56
  President 
Clinton remarked, “an apology is the first step, and we take it with a commitment to rebuild that 
broken trust.”57  The broken trust that continues to permeate in the African American community 
is a contributing factor that leads to lower level of black participation in medical studies.
58
  This 
mistrust and fear of medical researchers is now entrenched in the values and perceptions in the 
African American community.
59
   
                                                            
51. Id.  
52. Tuskegee Timeline.  
53. Racism and Research at 1.  
54. Tuskegee Timeline.  
55. Under the Shadow at 1773.  
56. The White House, Office of the Press Secretary, Remarks by the President in Apology for Study Done in 
Tuskegee (May 16, 1997), clinton4.nara.gov/textonly/New/Remarks/Fri/19970516-898.html.  
57. Id.  
58. Under the Shadow at 1773.  
59.  The Impact of Race and Genetics at 14, see also Ronald Roach, History's Burden: After Decades of 
Neglect, an Academic Research Agenda is Being Built Around Health Disparities, 20 BLACK ISSUES HIGHER 
EDUC. 1, 18 (May 8, 2003), available at findarticles. com/p/articles/mi_m0DXK/is_6_20/ai_101939864 
[hereinafter History's Burden] which provides insight on the impact of the Tuskegee experiment with respect to 
medical and public health professionals who attempt to treat diseases in the African American community; Shannon 
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B. The Current Paradigm for Drug Development & Clinical Trials  
 
 Over time many legal and ethical principles have evolved to protect patients who 
participate in clinical research.  This section will examine international codes of ethics and 
regulatory practices in the United States.  The Nuremberg Code, the Declaration of Helsinki, the 
Protection of Human Subjects regulation of 2009 and the NIH Revitalization Act of 1993 
provide domestic and international protections to patients who participate in clinical research.  
Many researchers abide by the Nuremberg Code and Declaration of Helsinki even though they 
are aspirational in nature because the United States has not formally adopted these codes of 
ethics.  Still, the Nuremberg Code and Declaration of Helsinki were influential in the United 
State’s effort to develop policies to guide research domestically.  
1. International Code of Ethics 
 
 The Nuremberg Code was implemented in response to the atrocities that occurred on 
concentration camps in Nazi Germany.
60
  The Nuremberg Code provides guidelines that should 
be followed when conducting clinical research, most importantly the necessity for voluntary and 
informed consent.
61
  This requires that participants are legally able to consent and freely 
acquiesce to participation without coercion, duress, or other unethical factors.
62
  In addition, the 
experiment should yield fruitful results for the good of society.
63
  Not only should the experiment 
                                                                                                                                                                                               
Mortland, Local Health Officials Rally to Steam Black's Cancer Fears, CRAIN'S CLEVELAND BUS., Aug. 28, 
2006, at 3 discussing African Americans mistrust of oncologist and attempts to remedy the issue by targeting 
minority populations to dispel widely held views. 
60. People & Events: The Nuremberg Trials, PBS, http://www.pbs.org/wgbh/amex/nuremberg/ (last visited 
March. 13 2013).  
61. Office of Human Subjects Research, Regulations and Ethical Guidelines, Nuremberg Code, Nat'l Insts. 
Health, available at http://ohsr.od.nih.gov/guidelines/nuremberg.html.  
62. Id.  
63. National Institutes of Health, “Trials of War Criminals before the Nuremberg Military Tribunals under 
Control Council Law No. 10,” Vol. 2, pp. 181-182. Washington, D.C.: U.S. Government Printing Office, 1949.,  
available at http://history.nih.gov/research/downloads/nuremberg.pdf  
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yield fruitful results, but the experiment should not involve physical or mental suffering.
64
  
However, the Nuremberg Code is not a part of legal jurisprudence in the United States; therefore, 
researchers are not obligated to follow its mandate although it is the norm.
65
 
 Likewise, the Declaration of Helsinki is not legally binding in the United States but 
provides ethical principles for researchers.
66
 Similar to the Nuremberg Code, the Declaration of 
Helsinki is concerned with voluntary participation and informed consent.
67
  “It is the duty of the 
physician to promote and safeguard the health of patients, including those who are involved in 
medical research.”68  The Declaration of Helsinki requires that the protocol include the design 
and performance of each study and any potential conflicts that may arise between physicians and 
institutions financially supporting the endeavor.
69
  The Nuremberg Code and Declaration of 
Helsinki were influential in the United State’s efforts to deal with unethical practices in 
research.
70
   
2.  U.S. Regulatory Protections   
  
 The United States passed the Protection of Human Subjects
71
 to address patient 
participation in research and the National Institutes of Health Revitalization Act of 1993 to 
                                                            
64. Id.  
65. See Generally Ravindra B. Ghooi, The Nuremberg Code – A Critique, 2:2 Perspect. Clin. Res. 72 (2011).  
66. World Med. Ass'n, Declaration of Helsinki - Ethical Principles for Medical Research Involving Human 
Subjects (2008), available at http://www.wma.net/en/30publications/10policies/b3/17c.pdf.   
67.  Id. 
68. World Medical Association, WMA Declaration of Helsinki – Ethical Principles for Medical Research 
Involving Human Subjects, last accessed (May 9, 2013)  available at 
http://www.wma.net/en/30publications/10policies/b3/.  
69. Id at para. 14.  
70. Matthew Anderson, FDA Abandons Declaration of Helsinki for International Clinical Trials, The Social 
Medicine Portal, (2008) available at http://www.socialmedicine.org/2008/06/01/ethics/fda-abandons-declaration-of-
helsinki-for-international-clinical-trials/.   
71. 45 C.F.R. § 46 (2009). 
11 
 
require researchers to include minorities in research.
72
  This section will now examine U.S. 
regulations that provide protections to participants in clinical trials.   
 i.  The Common Rule 
 The Protection of Human Subjects of 2009, also known as the Common Rule, is codified 
in the Code of Federal Regulations Title 45 Part 46.
73
  The Common Rule applies to research 
involving human subjects that is financed by federal government funding; takes place at a 
federally funded institution; or conducts research to support an application to the FDA.
74
  The 
Common Rule provides detailed requirements that researchers must abide by, and include but are 
not limited to, requirements for informed consent and the establishment of an Institutional 
Review Board [hereinafter IRB] for oversight.
75
     
 More specifically, each institution covered by the Common Rule must have at least one 
IRB, and before the covered research can begin research he or she must obtain approval from the 
IRB.
76
  The IRB is to function as an independent body whose goal is to protect the safety and 
welfare of the participants involved in the research by ensuring that the researchers are compliant 
with federal regulations.
77
  Most important, the IRB is tasked with ensuring that possible risks to 
the participants are minimized “by using procedures which are consistent with sound research 
design and which do not unnecessarily expose subjects to risk.”78   
                                                            
72.  National Institutes of Health Revitalization Act, Pub. L. No. 103-43, § 492B(a)(1) (1993) [hereinafter 
Revitalization Act]. 
73. 45 C.F.R. § 46 (2009).  
74. Id. at § 46.101 (2009).  
75. Id. at §§ 46.103, 46.116 (2009). 
76. Id. at § 46.109 (2009).  
77. Id. at § 46.107 (2009).  
78. Id. at §  46.111(a)(1) (2009). 
12 
 
 From a patient perspective, the Common Rule provides legal protection even when 
informed consent is followed.
79
  The Common Rule states “No informed consent . . . may 
include exculpatory language through which the subject . . . is made to waive . . . any of the 
subject's legal rights, or . . . to release the investigator, the sponsor, the institution or its agents 
from liability for negligence.”80  The provision is particularly important because if the patient is 
able to prove that the researcher fell below the acceptable standard in the performance of the 
research he or she may have a cause of action.  Similarly, the NIH Revitalization Act of 1993 
provides protections to ensure that minorities represented in clinical research.      
  ii.  NIH Revitalization Act of 1993 
 Because of the events blacks experienced with respect to clinical research, the legislature 
implemented the Revitalization Act of 1993.  Public Law 103-43 National Institutes of Health 
Revitalization Act of 1993 [hereinafter Revitalization Act], requires that members of minority 
groups be included as research participants in clinical research.
81
  In addition, the statute requires 
the National Institutes of Health [hereinafter NIH] to develop guidelines that governs when 
inclusion of minorities is inappropriate, “the manner in which clinical trials are required to be 
designed and carried out,” and “the operation of outreach programs.”82  The Revitalization Act 
also tasks the Director of NIH with the responsibility of ensuring that the trial is designed and 
carried out in a manner sufficient to provide for valid analysis of whether the variables being 
studied in the trial affect members of minority groups differently than other study participants.
83
  
This provision is especially important as it requires cross comparison between groups and 
                                                            
79. Matthew P. Gordon, A Legal Duty to Disclose Individual Research Findings to Research Subjects?, 64 
Food Drug L.J. 225, 231—32  (2009).  
80. 45 C.F.R. § 46.116 (2009).  
81. Id.  
82. Id. at § 492B(d)(1).  
83. Id. at § 492B(c).  
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prevents researchers from isolating certain populations, unless an exception applies, without 
cross referencing the drug’s effects on members of other groups.84 
 The Revitalization Act advances the position that minorities should be included in 
research by requiring that “the Director of the Office of Research on Minority Health, conduct or 
support outreach programs for the recruitment of members of minority groups as subjects in the 
projects of clinical research.”85  The Revitalization Act applies broadly except in cases where 
minority participation in the research “is inappropriate with respect to the health of the subjects, 
is inappropriate with respect to the purpose of the research, or is inappropriate under such other 
circumstances” identified by the Director of NIH.86  Similarly, minority participation in research 
is exempted where there is scientific evidence establishing no significant difference between the 
impacts the variables studied in the trial would have on minorities and the impact the variables 
would have on participants if the inclusion was not required.
87
    
 The NIH stands firm behind the policy that minorities should be included in clinical 
research “unless a clear and compelling rationale and justification establishes to the satisfaction 
of the relevant Institute/Center Director that inclusion is inappropriate with respect to the health 
of the subjects or the purpose of the research.”88 While the NIH policy is positive in theory and 
the federal statute establishes procedural requirements such as informed consent and other 
patient protections, these policies and laws are without effect if minorities do not participate in 
                                                            
84. Id. at § 492B(d).  
85. Id. at § 492B(a)(2).  
86. Id. at § 492B(b).  
87.  Revitalization Act at § 492B(d)(2). 
88. NIH, NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical 
Research, Amended October 2001 available at 
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.  
14 
 
the research.  “Black Americans tend to be under-represented in clinical trials, which are 
responsible for most advances in medicine.”89 
 In summation, international ethical principles and domestic regulations work together to 
provide patient protection.  Researcher institutions that receive federal funding are incentivized 
to adhere to the preapproved clinical protocol so that they can continue to receive federal funds.  
In addition, IRBs are in place and provide independent oversight over the clinical process.  The 
Common Rule specifically protects participants because researchers cannot provide oral or 
written exculpatory language to absolve themselves of liability.  Even more, if a participant can 
prove that the researcher was negligent, despite providing informed consent, he or she can 
recover damages.   
 However, these legal and regulatory safeguards fall short of protecting participants 
because minorities are not participating in research.  While the Revitalization Act mandates that 
minorities are included in research, African Americans remain disproportionately 
underrepresented.  African American’s perspectives on the adequacy of legal and ethical 
protections create a barrier that prevents them from participating in clinical researchers.  These 
perspectives are the subject of the next section.  
C. Minority Perspectives on the Adequacy of Protections in Clinical Trials 
 
 According to 2011 census data, African Americans make up approximately 13.1% of the 
United States population.
90
  As recent as 2009, African Americans comprise 15% of the 28.1% 
                                                            
89. Amanda Gardner, Black Americans Still Wary of Clinical Trials Study Shows Distrust of Researchers 
Lingers from Tuskegee Experiment, U.S. News & World Report, Jan. 14, 2008, available at 
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of minorities who participate in domestic clinical research.
91
  Minority distrust of clinical 
researchers is one of the reasons African Americans do not participate in research.
92
  “For many, 
this project [Tuskegee] represents the epitome of how racism is reflected in medicine and 
medical research as it is in general society.”93  Factors that weigh African American participation 
in research include “distrust owing to historical research abuse and institutional racism, lack of 
information and understanding of research and studies and informed consent, insufficient 
recruitment efforts by researchers, social stigma, and financial considerations.”94   
 In the professional realm, African Americans are underrepresented in the fields of 
medical and mental health, which further perpetuates levels of mistrust.
95
  Corbie-Smith and 
fellow researchers raise a very important point that was highlighted in their study of African 
American perceptions of clinical research -- “regardless of whether the instances participants 
provided as explanations are historically accurate, every instance is perceived as “real” in their 
minds.”96  The past still haunts many African Americans and dealing with those deeply rooted 
ideologies is an important step in increasing minority participation in research.
97
  “Knowledge of 
research procedures and purposes is often linked to access to health care.”98  But, Corbie-Smith 
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LAW & INEQUALITY 179, 189 (2012).  
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14 J. GENERAL INTERNAL MEDICINE 537, 543 (1999).  
97. Hsin-hsin, supra note 94 at 622.  
98. V.S. Freimuth, S.C. Quinn, S.B. Thomas, G. Cole, E. Zook, and T. Duncan, African American’s Views on 
Research and the Tuskegee Syphilis Study, 52 SOCIAL SCIENCE & MEDICINE, 797-808 (2001).  
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found that African Americans have an increased likelihood of being distrustful of physicians.
99
  
Physicians can serve as pivotal players in research protocols because they often are aware of 
research and can recommend participation in the studies.  However, because African Americans 
are distrustful of physicians, their level of distrust will override their inclination to participate in 
the study.
100
     
 Moreover, minority perspectives are shaped by the information that is available to 
them.
101
  Minorities do not participate in research because of lack of access to primary care 
physicians who often suggest participation in clinical research and their beliefs that studies do 
not apply to them, which in turn decreases minority participation in studies.
102
  In addition, 
because most people do not trust what they cannot understand, minorities are leery of 
participating in clinical trials when they cannot understand the informed consent documents.
103
  
African Americans, in particular, are concerned with social stigmatization and other 
consequences so they shy away from medical attention.
104
    
 Conversely, not all African Americans are reluctant to participate in clinical research.  
For those who choose to participate, literature suggests that altruism and volunteerism are 
contributing factors.
105
  Another motivating factor is family encouragement.
106
  However, one of 
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the leading barriers to minority participation in research is financial constraint; so for those who 
participate in clinical protocols, financial incentive is often a deciding factor.
107
  
 Nevertheless, efforts that encourage participation are curbed when “pharmaceutical 
companies discourage the recruitment of diverse populations.”108  Instead, research institutions 
should focus on resolving negative perceptions.  It is difficult to debunk negative perceptions and 
attitudes when companies continue to contribute to those negative perceptions by discouraging 
participation in research.  The NIH has identified circumstances when minority participation is 
excluded.
109
 Therefore, efforts to discourage participation should be redirected to debunking 
myths in the minority community.   
III. Health Indicators and Access to Drugs   
 
 The following section will examine health indicators specifically access to drugs.  Health 
indicators, to be fully discussed below, identify disparities in health by using measurable factors.  
Access to health is one of the measurable health indicators.  Lack of access to health in turn 
creates disparities in health and a trickledown effect.  Lack of access creates disparities in health 
care treatment which then impacts health care outcomes such as treatment for particular diseases 
and life expectancies in certain populations.  This section will now define access as a health 
indicator and followed by an analysis that explores the impact that results because of lack of 
access to health care treatment and prevention. 
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A. Determinants of Health as a Policy to Support Race-Based Medicine 
 
 Access to drugs, pharmaceuticals, and research is one means to measure health.  “Access 
is defined as having medicines continuously available and affordable at public or private health 
facilities or medicine outlets that are within one hour’s walk from the homes of the 
population.”110  Research shows that the uninsured, women in particular, have a greater difficulty 
accessing health care and use fewer services and preventive care.
111
  Approximately one in four 
blacks rely on Medicaid for healthcare in comparison to one in eight whites.
112
  It is difficult for 
minorities to access care because factors such as low reimbursement rates, administrative 
burdens, and residential segregation between providers and patients create barriers to access.
113
 
 Health indicators are defined as “measurable characteristics that describe the health of a 
population; determinants of health; and health care access, cost, quality and use.”114  The health 
of a population can be measured in terms of life expectancy, mortality, disease incidence or 
prevalence and or any other health states.
115
  Health determinants are influenced by health 
behaviors, health risks factors, socioeconomic and physical environments.
116
  Health indicators 
are useful for measuring how certain identifiable groups access health care and health care 
related services.
117
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  Researchers have examined three core areas as they relate to disparities in health.
118
  The 
first core area researchers have explored are disparities that involve differences in the type of 
treatment offered to patients.
119
  Socioeconomic factors have contributed to health disparities 
especially as it relates to access to care.
120
  Not only do socioeconomic factors impact access to 
care, but socioeconomic factors also affect the type of treatment offered to the patient and is a 
determinate of whether the patient accepts the proposed treatment.
121
  At the intersection of 
health indicators and health disparities, researchers have been able to identify how race, 
socioeconomic factors, and biological factors impact access to and quality of care.
122
  
Unfortunately, African Americans are less likely to receive medically appropriate care even 
when socioeconomic and access to care factors is controlled i.e. when examining African 
Americans to Caucasians in the same socioeconomic status.
123
   
 A second core area of research has focused on particular conditions and the health 
outcomes that result from those various conditions.
124
  These studies are particularly important 
for researchers in the pharmaceutical industry because it would support assertions that 
researchers make when holding that certain medicines are not fit for a particular population.  The 
government requires that when certain racial or gender groups are excluded from research that 
the researcher provide evidence that the group would be harmed in some way or that the research 
would not be beneficial.  Where a research can show that a particular treatment will harm a 
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group s/he is insulated from governmental scrutiny.  In fact, biology alone can create health 
disparities and not wrongdoing on the behalf of researchers.
125
  
 The third core area of research explores disparities in health status for example 
differences in life expectancy and prevalence of certain diseases for certain groups.
126
  Health 
status directly correlates with gender.
127
  Men have a life expectancy that is five years less than 
that of women.
128
  The Centers for Disease Control uses life expectancy to measure health.
129
  
From 1980 to 2008, life expectancy at birth increased six years for males rising from 70 to 76 
and four years for females from 77 to 81 years.
130
  However, African Americans still lag behind 
in life expectancy when compared to their Caucasian counterparts.
131
  African Americans have a 
life expectancy of 70 years for males compared to 78 years for Caucasian males and 77 years for 
African American females compared to 83 years for Caucasians females.
132
  “That disparities in 
health status mirror patterns of historical discrimination in society is at least cause for alarm, and 
perhaps action as well.”133  There are many factors that impact health disparities and access to 
health care and it is crucial that the actual cause is identified to remedy and address the problems 
African Americans face as identified by health indicators.  One way to identify and address 
health problems in the African American community is through race-based medicine.     
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B. Race-Based Medicine a Misunderstood Clinical Research Practice 
 
 Race-based medicine is a subset of pharmacogenomics, which involves the sequencing of 
the human genome to better understand disease and pharmaceutical mechanisms for an 
individual patient.
134
  Race-based medicine can be defined as “screening, diagnosis, or treatment 
based on the appointment of an individual to a specific subpopulation associated with his 
physical characteristics, language, or, perhaps, surname, which is presumed to serve as a marker 
of the geographic origins of one’s ancestors.”135  One goal of race-based medicine is to explore 
racial ancestry to better identify genetic predispositions for diseases.
136
  It is crucial that patients 
and researchers understand the difference between social race and biological race.
137
  Social race 
as distinguished from biological race is the ideology that taking an individual’s perception and 
combining society’s perception of the individual impact the ethnic or racial group within which 
the individual is a member.
138
  On the other hand, biological race examines race in the context of 
ancestry.
139
  Although there is a history of racially motivated research, some argue that race is no 
longer a factor that impacts research.
140
 
 Race-based medicine is highly debated both in theory and in practice because on the one 
hand race-based medicine could advance medicine, but on the other hand it could negatively 
perpetuate stereotypes and ideologies of certain groups.  “Although it is recognized that ideology 
influences the social meaning of race, it is usually assumed that there is a separate, prior 
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scientific understanding of race that is not contaminated by politics.”141  Critics of race-based 
medicine argue that race should not be used because “race has no coherent meaning, and 
therefore, reliance upon it for research or treatment purposes can be confusing at best and can 
lead to significant adverse consequences at worst.”142  However, the truth remains that there are 
differences in life expectancy between racial groups, differences in metabolic rates of nicotine 
from cigarette smoking, and differences in hypertension rates.
143
  Examining how race and other 
health indicators factor into overall health is important so that healthcare players such as 
lawmakers, researchers, doctors, and community activist; can better close the divide between 
racial groups and health care disparities. 
 Scholar of race, gender and law, Dorothy Roberts, identifies “conservative colorblind 
ideologists” as those who assert that differences between racial groups are based on unbiased 
market operations, that racism is no longer a factor socially, and that social policies should not 
use race as a basis for policy determinations.
144
  Conservative colorblind ideology is an extreme 
view for some to conceptualize.  However, there is some merit to the idea in the biological 
research realm.  In biological research, race remains a factor in medical research and because of 
these differences between groups it is important for researchers to fully explore these differences 
when developing medicines.
145
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 Acknowledging the fact that there are differences between races is key in closing the gap 
in health disparities.  The next step is to make clear that while there are biological differences 
between groups, the race of the individual will not interfere with the ethical obligations of the 
researcher.  The conservative’s view of racial colorblindness intersects with the identity-based 
ideologist because both groups share the view that race matters in medicine.  Identity-based 
ideologists are race conscious and assert that programs that use race as a basis for funding are 
important for advancing medicine.
146
  Race-conscious efforts are implemented to correct past 
wrongs and in doing so also advance current colorblind paradigms.
147
  One example that has 
been particularly beneficial for African Americans is the drug BiDil.  BiDil is a drug specifically 
targeted at African Americans and has created an alliance between the pharmaceutical world and 
racial organizations such as the National Association for the Advancement of Colored People 
(NAACP). As a result, the pharmaceutical company and national association can work together 
to close the gap in health disparities.
148
   
IV. BiDil 
 
 The drug BiDil has an interesting past despite its positive results in the African American 
community.  The first study of BiDil failed to receive Federal Drug Administration [hereinafter 
FDA] approval.
149
  The first FDA application was submitted in 1997, but the results failed to 
show sufficient statistical efficacy for a multiracial population with heart disease.
150
  “On the 
recommendation of members of FDA's advisory committee, NitroMed re-examined the clinical 
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trial data along racial lines.”151  It was from this data that the researchers began a second study 
that later would receive FDA approval. The drug is criticized for promoting counterproductive 
healthcare policy.  The FDA, by approving BiDil, also approved a biological model for race.
152
  
“Because the FDA had no clinical evidence on which to base its drug approval for a specific 
race, the approval is implicitly based on an assumed biological difference between black and 
nonblack patients.”153  The clinical researchers failed to cross compare populations to determine 
whether there was a significant difference when determining the efficacy of the drug.
154
  This 
section will now examine how the drug BiDil was developed and its social, political, and 
commercial implications. 
1. Development of the Drug BiDil 
 The FDA announced in June 2005 that it approved for the first time a pharmaceutical 
drug specifically targeted for African Americans.
155
  BiDil is a combination of two generic drugs 
hydralazine and isosorbide dinitrate.
156
  BiDil works to treat heart failure by relaxing the blood 
vessels surrounding the heart.
157
  The drugs themselves are not new to the market, but rather their 
combination and concentration is a new drug.  It is widely viewed by the public as the world’s 
first “ethnic” drug.158      
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 The study was entitled the African American Heart Failure Trial [hereinafter A-HeFT].
159
  
The study enrolled 1,050 black patients who had New York Heart Association class III or IV 
heart failure with dilated ventricles.
160
  A-HeFT was a randomized, placebo-controlled, double-
blind trial with patients recruited at 161 centers in the United States.
161
   Half of the study 
participants were treated with the combination drug and the other half the placebo along with 
standard therapy used for heart failure.
162
  This study in comparison to the unethical studies in 
the early 20th century were reviewed and approved by the institutional review board at each site 
and all patients gave written informed consent.
163
 The study sponsor was NitroMed, a 
Massachusetts based biotechnology firm.
164
   
 This study is important for two reasons.  First, the study was proven efficacious for a 
group that traditionally lacks access to proper medical care.  Second, the study is important 
because it provides empirical evidence that researchers are able to implement ethical studies that 
do not compromise the lives of the study participants.  In the A-HeFT study, independent 
committees assessed all primary and secondary end points, reviewed data on safety, and oversaw 
the two prespecified interim analyses, which were performed solely to assess the adequacy of the 
sample size.
165
 
 Although the study was terminated prematurely because many of the patients on the 
placebo experienced higher mortality, the results showed that patients who were treated with the 
drug combination hydralazine and isosorbide dinitrate along with standard therapy for heart 
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failure had an increased chance of survival among black patients with advanced heart failure.
166
  
While all of the study participants were African American, the trial investigators presented that 
drug as effective in other racial groups as well.
167
   
 The A-HeFT study published by the New England Journal of Medicine establishes that 
the drug is efficacious in the population studied, African Americans.
168
  There was a 43% 
reduction in mortality rate in the group given the combination drug, supporting the conclusion 
that the drug controls heart failure.
169
  The drug BiDil is wiedly criticized on social and political 
levels in spite of the drugs proven efficacy in the African American population.   
2. Criticisms of BiDil  
 
 Critics of the A-HeFT study do not believe that the drug can be marketed as beneficial for 
African Americans because there was no comparison population.
170
  “The only responsible claim 
that can be made on the basis of these trials is that BiDil works in some people who have heart 
failure.”171  The study has been criticized on three levels:  scientific, commercial and political.172  
“By claiming that race, a political grouping, is important to the marketing of drugs and that race-
based drugs can reduce health disparities, which are caused primarily by social inequality, those 
who promote racialized medicine have made it a political issue.”173 
 Scientifically there are widespread criticisms to the use of race-based medicine; the more 
important question to explore is whether race-based medicine can reduce health disparities.  
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Medical research should by no means perpetuate stereotypes and racism, but if race-based 
medicine can close the gap in the health indicators that relates to access to care, perhaps race-
based medicine is a solution and not an actual problem.  Next, this paper will address whether 
the critiques of BiDil address closing the gap in health disparities or are aimed at some other 
social issue.  It is important, as highlighted earlier, to maintain a dividing line between race as a 
sociological issue and race as a biological/medical issue.     
 In the political arena, the FDA is criticized for approving the drug BiDil because the drug 
is targeted for a specific population, African Americans.
174
  Historically, the FDA has 
discouraged clinical research practices that take advantage of marginalized groups.
175
  It is 
argued that the FDA’s decision “may be a setback to scientific discourse on therapeutics and 
may be specifically deleterious to efforts aimed at addressing disparities in health and health 
care.”176  BiDil has further been criticized for exploiting the African American community for 
corporate profit and two a poor precedent of racial segregation in medicine.
177
  Even more, the 
drug was marketed as a race specific treatment, but in reality there was evidence that the drug 
was effective across racial lines.
178
  
 Commercially, the drug is criticized for its price because the generic drug was priced 
significantly lower at approximately $1.50-$3.00 while BiDil was priced at $5.40-$10.80 per day 
for treatment.
179
  It would seem that if the goal were to increase access to health care and 
decrease disparities in the provision of health, the drug manufacturer would have priced the drug 
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in a range that was affordable for the population.
180
  Despite the discounts and gratuitous 
availability of the drug for certain groups, cardiologists argued that the drug cost exceeded many 
patients’ financial ability to pay.181  However, accounting for insurance and other factors it is 
arguable whether the cost of the drug is commercially exploiting the African American 
population. 
   Researchers have attempted to remedy a healthcare disparity by disseminating 
information that may not be based on scientific evidence.
182
  The question then becomes are 
researchers advancing genetic revolution or are they perpetuating stereotypes?
183
  The FDA is 
sending mixed signals by approval of the drug BiDil.  On the one hand, researchers are required 
to follow certain clinical guidelines when race is a factor.
184
  On the other hand, the FDA has 
approved the use of race as a factor when it seems to decrease health disparities, but it is argued 
that this erodes the advancements that were made to create equal treatment in the clinical 
research setting.
185
 
V. Race-Based Medicine as a Means to Reduce Health Disparities 
 Despite the controversy surrounding the drug BiDil, there are benefits to the drug’s use.  
There are many theories that describe why African Americans are more likely to die of heart 
failure in comparison to whites.
186
  Some contributing factors to higher prevalence of heart 
failure in African Americans in comparison to whites include delay in diagnosis treatment, 
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physical inactivity, and smoking.
187
  A group of social scientists reviewing genomic science 
argue that “we must continue to do research on race in medicine because whatever its biological 
basis race remains a very important social construct, and as such, it has tremendous power to 
influence health and illness.”188  There are social and cultural factors that can contribute to higher 
prevalence of certain diseases in certain populations and exploring drugs such as BiDil allows 
researchers to examine these crucial contributing factors.
189
  “Simply eliminating race as a 
variable in medical research would undermine our ability to detect these factors and can 
therefore hardly be helpful in reducing the serious disparities that remain a problem in American 
medicine.”190 
 The development of the drug BiDil is a reason to celebrate not only for the scientific 
advancement, but also for the cultural and social advancement.
191
  In light of the historical 
injustices surrounding African Americans and scientific research, the development of BiDil 
should be seen as a step in the direction of removing discrimination in research.
192
  When race is 
a contributing factor in research it is not to perpetuate racism or discrimination, but rather race is 
a “placeholder” so that researchers can fully examine differences among groups of people.193  
“Finding these variations (and their physiological manifestations) and then linking these 
variations to differences in therapeutic efficacy” is the benefit race-based medicine.194   
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   Race-based medicine as a research approach is most supported by the development of 
the drug BiDil.
195
  Creating BiDil is one of the first attempts to remedy claims of misrecognition 
in research and also increase minority participation in clinical trials.
196
 African Americans have 
distrusted researchers since the occurrence of the racially charged atrocious acts, slavery and the 
Tuskegee experiment.
197
   
 BiDil should be viewed as not only a drug development, but also as a socially progressive 
movement that can increase minority participation in research and also prove that researchers 
respect African Americans and have their best interest in mind.  In the following section, I will 
explore recommendations for dealing with lack of minority participation in clinical trials by way 
of public health and community based approaches that educate and encourage minorities to trust 
their physicians and researchers.  
VI. Recommendations and Conclusion  
 
 Remedying past discrimination in clinical research to encourage minorities seems like a 
formidable task.  “The family medicine community ought to encourage continued action to 
reduce health disparities, to promote research that addresses the psychological and social 
contributors to ill health alongside the biological factors.”198  Unfortunately, minorities remain 
very distrustful of physicians and clinical researchers.  Racial tensions have loomed among 
African Americans for decades, but if race-based medicine can remedy health disparities it 
should be pursued.  One perspective to address this challenge is a public health perspective.  The 
World Health Organization (WHO) defines public health as “all organized measures (whether 
public or private) to prevent disease, promote health, and prolong life among the population as a 
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whole. Its activities aim to provide conditions in which people can be healthy and focus on entire 
populations, not on individual patients or diseases.”199  Disparities in health care access trickle 
down and have various effects on African Americans.  Public health would support measures 
that prevent disease and prolong life among populations, in this case African Americans.  Public 
health initiatives that promote increased transparency in clinical trials would help to develop 
bonds of trust between minorities and researchers.   
 In 2010, the University of Minnesota received a $3.8 million dollar grant from the 
National Institutes of Health’s National Cancer Center on Minority Health and Health 
Disparities.
200
  Researchers are aware that, while there are racial differences in prevalence among 
diseases, social and environmental factors also impact health disparities.
201
  “We need not shy 
away from the potential benefits of race-conscious therapeutics, but we should manage its 
downside risks, greater awareness among physicians and the public that race is at best a 
placeholder for other predispositions, and not a biologic verity, would be a first step.” 202  
Medical researchers and clinical researchers alike should not avoid racial differences in groups 
because it does these groups a disservice.  Instead, researchers should face these racial 
differences head on to further understand why certain diseases are more prevalent among 
minorities.  The efforts at the University of Minnesota are one step in that direction.  The 
University of Minnesota has identified a group of people, African Americans, who suffers with a 
health issue and aims to help remedy that issue by educating minorities and encouraging 
participation in clinical trials.   
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 In addition to university sponsored events, primary care physicians assist in building trust 
among minorities.  Physicians interact with patients on a one-on-one level and are better able to 
address distrustful concerns.  To address patient distrust, physicians should increase dialogue and 
find out what concerns minorities face.  Preconceived notions and ideas about researchers may 
be deeply engrained in African American culture, but physicians should take the angle that 
quality of life increases with better health and with better health researchers must understand 
how to remedy health issues and without minority participation in research there is no way to 
understand why illnesses plague that group. 
 Moreover, legislative initiatives that subsidize costs to increase minority participation in 
research would encourage pharmaceutical companies to expend more money on minority 
recruitment.  In pediatrics for example the government awards financial incentives for research.  
The Best Pharmaceuticals for Children Act passed in 2002 provides pharmaceutical companies 
with extended market exclusivity on drugs developed for children.
203
  Because manufacturers 
have longer market exclusivity on drugs they are able to increase profit which is also an 
incentive for pharmaceutical companies to research illnesses facing children.  Similarly, the 
government should offer some incentive, be it longer market exclusivity or the government 
subsidizing costs to address distrust among minorities to in turn increase participation.   
 All in all, it is challenging remedying distrust in African Americans because of past 
events and distrustful attitudes carrying from generation to generation.  On a simpler level, 
having participants in research attest to their experiences in clinical trials could help debunk 
negative ideologies.   The fact remains that there are health care disparities; however, taking a 
public health approach, encouraging relationships between primary care physicians and patients 
and increasing financial incentives could begin to remedy distrustful attitudes.  Addressing the 
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issue head-on will then allow greater freedom in clinical research so that researchers can 
examine race-based issues without public outcry and distrust. 
 
  
